Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.
Ultragenyx Pharmaceutical Inc. (RARE) had Net Income of $-114.95M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$166.50M |
|
|
Net Income |
$-114.95M |
$23.00M |
|
$143.49M |
|
$274.38M |
|
$-107.89M |
|
$-6.12M |
|
$-114.00M |
|
$-114.00M |
|
$-114.95M |
|
$-114.95M |
|
$-114.95M |
|
$-114.95M |
|
$-107.89M |
|
$-100.32M |
|
98.46M |
|
98.46M |
|
$-1.17 |
|
$-1.17 |
|
| Balance Sheet Financials | |
$719.79M |
|
$255.76M |
|
$586.48M |
|
$1.31B |
|
$293.24M |
|
-- |
|
$861.74M |
|
$1.15B |
|
$151.29M |
|
$-67.85M |
|
$151.29M |
|
96.35M |
|
| Cash Flow Statement Financials | |
$-274.75M |
|
$191.06M |
|
$83.81M |
|
$184.16M |
|
$188.64M |
|
$4.49M |
|
$78.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.18% |
|
-64.80% |
|
-64.80% |
|
-- |
|
-68.47% |
|
-69.04% |
|
$-278.53M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.49 |
|
1.34 |
|
67.28 |
|
-75.98% |
|
169.41% |
|
-8.80% |
|
-75.98% |
|
$1.57 |
|
$-2.83 |
|
$-2.79 |
|